Financings in Brief: Sunrise Technologies
This article was originally published in The Gray Sheet
Sunrise Technologies: Nets approximately $2.3 mil. from private placement of 2.3 mil. shares of Sunrise stock. Proceeds will be used to support ongoing Phase II clinical trials for the Fremont, California-based firm's Holmium LTK laser thermal keratoplasty corneal shaping system for treatment of hyperopia, further R&D and general expenses ("The Gray Sheet" Nov. 21, 1994, p. 13). The placement was facilitated by Pennsylvania Merchant Group...
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.